More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The more an individual’s score changes, the greater the odds are of them being diagnosed with cancer in the near future, new research presented at SIIM 2024 suggests.
The new data suggest that admitting patients for observation and additional imaging to monitor for delayed intracranial hemorrhage might often be unnecessary.
Veteran cardiologist Harlan M. Krumholz, MD, has a long history in medical research as both an author and an editor. He and his team want to review manuscripts quickly and publish a wide variety of voices.
